With the increasing prevalence of pneumococcal diseases, government organizations across various countries are introducing programs to promote the use of pneumococcal vaccines. For instance, UNICEF along with the WHO has launched the Global Action Plan for Pneumonia and Diarrhea (GAPPD) to control incidence and mortality rate in children suffering from severe diarrhea and pneumonia by 2025. The investment in developing countries has also increased to help in the development and delivery of vaccines. For example, GAVI is a vaccine alliance that brings together public and private sector to offer immunization to the children in world’s poorest countries.

Global Pneumococcal Vaccines Market

The high cost of advanced vaccines is one of the factors hampering the growth of the market. However, manufacturers are competing for development of cost-effective and high quality of vaccines by focusing on research and development activities.  

According to the report by Transparency Market Research (TMR), the global market for pneumococcal vaccines is likely to witness robust growth, registering 8.3% CAGR between 2017 and 2026. The global market for pneumococcal vaccines is also projected to bring in US$ 20,515.5 million revenue by 2026 end.

13- Valent PCV to be the Top-Selling Product in the Global Market for Pneumococcal Vaccines

Compared to the various products, 13- valent PCV is likely to emerge as one of the top-selling product in the global market for pneumococcal vaccines. By 2026 end, 13- valent PCV is projected to bring in close to US$ 9,500 million revenue. PVC13 has offered a significant benefit in reducing carriage of Antibiotic-Nonsusceptible Streptococcus Pneumoniae (ANSP). Moreover, 13- Valent PCV includes thirteen serotypes of pneumococcus, also, serotypes 19A and 6A are present only in PCV13. The Centers for Disease Control and Prevention (CDC) has also recommended PCV13 for adults above the 65 years of age.

Hospitals to Emerge as the Largest Distribution Channel

Pneumococcal vaccines are likely to be distributed by Hospitals on a large scale between 2017 and 2026. Hospitals are projected to surpass US$ 12,400 million revenue towards the end of 2026. Increasing number of patients are being hospitalized for various infections and diseases, hence hospitals are emerging as the biggest distribution channel for pneumococcal vaccines, thereby reducing mortality associated with the pneumococcal infection.

North America to be the Largest Region in the Global Market for Pneumococcal Vaccines

North America is likely to emerge as one of the biggest regions in the global market for pneumococcal vaccines during 2017-2026. Pneumococcal Conjugated Vaccine (PCV) is the part of routine vaccine immunization in Canada and the U.S., since 2000. The countries have also witnessed highly-effective results since the vaccine was introduced. Investments by the government organization and private companies have also increased for promoting vaccination and towards the research and development of new vaccines. North America has also emerged as a main center for many vaccine producing companies.

Meanwhile, PCV is also the part of the vaccination program in countries like the Netherlands, Germany, Slovakia, Albania, Greece and Serbia. Increasing incidence of pneumococcal disease in various countries in APEJ also presents an opportunity for companies producing pneumococcal vaccines. Brazil is also witnessing a significant increase in pneumococcal diseases. Hence, various programs are being introduced in Brazil to increase the vaccine coverage.

Competition Tracking

The report provides a detailed analysis of the leading companies operating in the global market for pneumococcal vaccines such as Merck & Co. Inc., Pfizer, Inc., Sanofi, and GlaxoSmithKline PLC. The companies are focusing on the research and development of new pneumococcal vaccines. There has also been an increase in partnership between the leading companies and distributors in order to expand in the global market.

Global Pneumococcal Vaccines Market- Overview

The prevention of disease through vaccination is one of the most cost-effective and safe ways. Pneumococcus is one of the leading causes of blood infection, pneumonia, sinusitis, meningitis, and otitis media. It is also one of the leading infectious diseases. However, it can be prevented with the help of vaccination. With an increase in pneumococcal disease due to causative serotype, the need for vaccines with broader coverage has increased. Hence, the demand for new pneumococcal vaccines with broader serotype coverage is increasing.

Despite the availability of antibiotic therapy against pneumococcal disease, it remains a significant cause of death among people with increased susceptibility, such as older adults and also the people suffering from immunosuppressive conditions or chronic illness. However, reduction in the pneumococcal disease has been witnessed in the countries that introduced pneumococcal conjugate vaccines (PCV).  Meanwhile, efforts are underway to introduce pneumococcal vaccines in other countries as well. Companies are also working on introducing new and affordable PCVs, especially for developing countries. There has also been an increase in investment in the research and development activities to develop new vaccines at lower cost.

Global Pneumococcal Vaccines Market – Scope of Study

The research report on the global pneumococcal vaccines market offers key market insights and factors playing an important role in the market growth. The report provides information on market dynamics including trends, factors driving the market, opportunities, and restraints.  Key developments in the market are also provided in the report. The report also offers analysis and forecast on various market segments and regions.  

The report offers detailed study on the present and upcoming opportunities and developments along with advancement in technologies. Porter’s five force model along with SWOT analysis is also given in the report. The report has also evaluated market attractiveness. The global pneumococcal vaccines market displays the revenue, market share, growth rate for segments as well as regions.

The primary and secondary research has been done to offer both quantitative and qualitative data. The detail on leading players operating in the market along with the business strategies and new developments has also been provided in the report. Also covered in the report are regulations, ongoing research and developments in various countries. This will help the companies to make important business decisions to strengthen their position in the market.

Global Pneumococcal Vaccines Market- Key Segments

The global pneumococcal vaccines market is divided into product type, distribution channel, and region. Product type is further segmented into 7- valent PCV, 10- valent PCV, 13- valent PCV, and 23- valent PPSV. On the basis of distribution channel, the market is segmented into hospitals, clinics, and other distribution channels.

Region-wise, the market is segmented into Europe, Japan, Latin America, North America, Asia Pacific Excluding Japan (APEJ), and the Middle East and Africa (MEA). This segmentation also offers country-wise analysis on all the key parameters associated with the global pneumococcal vaccines market.

Global Pneumococcal Vaccines Market- Competitive Landscape

The report offers competitive landscape including vital information on some of the leading players contributing towards the market expansion. Some of the leading players operating in the market are Pfizer, Inc., GlaxoSmithKline PLC, Merck & Co. Inc., and Sanofi. The report offers detailed profile on each of the players including company overview, key strategies, financial overview, latest developments, and product portfolio.